{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:57Z","timestamp":1792068897934,"version":"4.4.0"},"reference-count":4,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom & Syst Pharma"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1002\/psp4.70350","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:34:51Z","timestamp":1792067691000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply\u00a0to \u201cAflibercept 8\u2009mg: From Ocular Clearance to Pharmacodynamic Duration\u201d"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2326-3335","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Bihorel","sequence":"first","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6715-8260","authenticated-orcid":false,"given":"Joannellyn","family":"Chiu","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Chittenden","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-3423","authenticated-orcid":false,"given":"Thomas","family":"Eissing","sequence":"additional","affiliation":[{"name":"Bayer AG  Leverkusen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Turner","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"H\u00f6chel","sequence":"additional","affiliation":[{"name":"Bayer AG  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqing Will","family":"He","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Davis","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4085-1577","authenticated-orcid":false,"given":"Lutz O.","family":"Harnisch","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"e_1_2_1_6_2_1","unstructured":"Health Canada \u201cClinical Overview (Section\u00a02.5 of eCTD) \u201d(accessed September 1 2026) https:\/\/clinical\u2010information.canada.ca\/ci\u2010rc\u2010vu.pdf?file=m2\/25\u2010clin\u2010over\/clinical\u2010overview.pdf&id=285427."},{"key":"e_1_2_1_6_3_1","unstructured":"European Medicines Agency \u201cEuropean Public Assessment Report Eylea\u2010H\u2010C\u20102392\u2010X\u201084\u2010G \u201d(accessed September 1 2026) https:\/\/www.ema.europa.eu\/en\/documents\/variation\u2010report\/eylea\u2010h\u2010c\u20102392\u2010x\u201084\u2010g\u2010epar\u2010assessment\u2010report\u2010variation_en.pdf."},{"key":"e_1_2_1_6_4_1","unstructured":"European Medicines Agency \u201cEuropean Public Assessment Report Eylea\u2010VR\u20100000264981 \u201d(accessed September 1 2026) https:\/\/www.ema.europa.eu\/en\/documents\/variation\u2010report\/eylea\u2010vr\u20100000264981\u2010epar\u2010assessment\u2010report\u2010variation_en.pdf."},{"key":"e_1_2_1_6_5_1","unstructured":"A.Perez\u2010Pitarch S.Bihorel K.Turner et\u00a0al. \u201cPharmacokinetic\/Pharmacodynamic Modeling and Simulation to Characterize Patients Who May Benefit From Monthly Dosing With Aflibercept 8 mg \u201dPoster Presented at Population Analysis Group in Europe; Dubrovnik Croatia (2026) https:\/\/www.page\u2010meeting.org\/?abstract=12138."}],"container-title":["CPT: Pharmacometrics & Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.70350","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/psp4.70350","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.70350","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:34:52Z","timestamp":1792067692000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.70350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":4,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1002\/psp4.70350"],"URL":"https:\/\/doi.org\/10.1002\/psp4.70350","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"2026-09-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70350"}}